Health inspection·April 29, 2025

F 0756 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Some Ensure a licensed pharmacist perform a monthly drug regimen review, including the medical chart, following irregularity reporting guidelines in developed policies and procedures. **NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on review of pharmacy recommendations and interviews, the facility failed to ensure the attending physician documented in the residents medical records the rationale for not acting on and following pharmacy recommendation for two (#2 and #19) of three residents reviewed for pharmacy recommendations. Findings included: Review of Resident #2's medical record documented an admission date of 2/16/2024 and included the following diagnoses: depression, anxiety disorder, pulmonary hypertension a type of high blood pressure that affects the arteries in the lungs), emphysema (a disorder that affects the tiny air sacs in the lungs), and pulmonary fibrosis (scarring of the tissue around the airs sacs in the lungs). Review of the document tiled, Consultant Pharmacist's Report for Resident #2 recommendation date of 2/23/2024 reads, Findings/Recommendations: New admission medication regimen review. admission summary: This 77 y/o (year old) resident was readmitted on [DATE]. #1) Beers drug/potentially inappropriate medication: Xanax 0.25 mg (Milligrams). Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting agents: Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. In general, all benzodiazepines increase risk of cognitive impairment, delirium, falls and fractures in older adults. Consider deprescribing by gradually tapering by 25% every 2 weeks in partnership with patient. Disagree was checked. The review showed there was no rationale documented from the attending physician on the recommendation form or within the medical record. Review of Resident #19's medical record documented a readmission date of 2/27/2025 and included the following diagnoses: urinary tract infection, traumatic subarachnoid hemorrhage (bleeding in the space between the brain and the membrane that covers the brain) without loss of consciousness, weakness, repeated falls, and essential primary hypertension ( high blood pressure). Review of the document tiled, Consultant Pharmacist's Report for Resident #2 recommendation date of 3/2/2025 reads, Findings Recommendations: New admission Medication Regime review. admission summary : This 80 y/o resident was readmitted on [DATE]: #1 Duplication in therapy Concomitant use of the following medications represents a duplication in therapy:#1) Bupropion XL 300 mg and Fluoxetine 40 mg for depression Please attempt a dose reduction to: Bupropion XL 150 mg po (by mouth) once daily documented disagree, no rationale was provided. The review showed, *Note*: This resident has a history of falls. The current medications listed below may have contributed to the fall. Concurrent use of these medications may increase side effects such as dizziness, drowsiness, confusion, falls, (continued on next page) Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation. LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE TITLE (X6) DATE FORM CMS-2567 (02/99) Previous Versions Obsolete Facility ID: If continuation sheet Page 1 of 5 Event ID: 105544 Printed: 05/28/2026 Form Approved OMB No. 0938-0391 Department of Health & Human Services Centers for Medicare & Medicaid Services STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION (X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: (X2) MULTIPLE CONSTRUCTION 105544 B. Wing A. Building (X3) DATE SURVEY COMPLETED 04/29/2025 NAME OF PROVIDER OR SUPPLIER STREET ADDRESS, CITY, STATE, ZIP CODE Solaris Healthcare Bayonet Point 7210 Beacon Woods Dr Hudson, FL 34667 For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency. (X4) ID PREFIX TAG SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)